Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Clinical Trials in France / NCT03479580
Recruiting Observational

Coronary Artery Disease and Coronary Microvascular Disease in Cardiomyopathies Registry

NCT03479580 · tracked via the Priya Life Science France tracker
Sponsor
University Hospital, Grenoble
Phase
Observational
Started
2018-02-08
Last updated
2022-05-19

Condition(s) studied

HypertrophicIschemicRestrictive CardiomyopathyDilated Cardiomyopathies

Investigational drug(s) / intervention(s)

Patients with a cardiomyopathy

Patients with a cardiomyopathy: Prognostic value of coronary artery disease and microvascular disease in the different types of cardiomyopathies.

Study summary

Long-term prognostic value of macrovascular and microvascular coronary artery stenoses in each type of cardiomyopathy.

Eligibility

Sex
ALL
Min age
18 Years
Max age
100 Years
Healthy volunteers
No
Inclusion Criteria: * Ischemic * Dilated * Hypertrophic * Restrictive cardiomyopathy. Exclusion Criteria: * Pregnant women * Breastfeeding women * Patients under legal protection

Primary outcome measure(s)

  • Major Adverse Cardiovascular Events — 5 years
    Composite outcome = rate of cardiovascular death, non-fatal myocardial infarction, need for myocardial revascularization by coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI) \> 3 months after enrollment. During follow up

Trial sites (1)

FacilityCityRegionStatus
University Hospital Grenoble La Tronche France Recruiting

More University Hospital, Grenoble trials in France

Circulating Cell-Free DNA for Brain Abscess Diagnosis: A Pilot Study Starting soon
Evaluation of the Feasibility and Efficacy of a Chronic Brain-computer Interface for Speech Rehabilitation in Patients With Locked-in-syndrome (LIS) Starting soon
Satisfaction of Specific Modes Related to Physical Activity in People Living With Type 1 Diabetes and Using an Hybrid Closed-loop System Recruiting
City-Hospital Collaboration for Early Detection of Liver Fibrosis in Primary Care: A Secondary Prevention Project in the Grenoble Health Area Recruiting
Chest Pain Nurse Track Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT03479580 on ClinicalTrials.gov ↗ ← All trials in France